The new Indian Council of Medical Research (ICMR) study shows that lung cancer incidence will be the highest in the ...

Researchers and health experts in India are raising the alarm that lung cancer, long linked to smoking, is increasingly ...

India is likely to witness a sharp rise in lung cancer cases by 2030, with the North-East emerging as the most affected ...

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

The Signatera assay showed positive correlations between ctDNA presence and cancer recurrence, suggesting its potential for ...

RVMD stays a Strong Buy as RAS inhibitor trials advance; phase 3 RASolute-302 is a key 2026 catalyst. Read the latest ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

HOUSTON, JANUARY 9, 2026 ― At The University of Texas MD Anderson Cancer Center , research breakthroughs are made possible through seamless ...

Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...